AbbVie Ventures took a board seat through its contribution to the round, closed as the inflammatory disease therapy developer emerged from stealth.
US-based inflammatory disease drug developer Quench Bio launched yesterday with $50m of series A funding from investors including Abbvie Ventures, the corporate venturing subsidiary of pharmaceutical firm Abbvie.
The round was led by investment management firm RA Capital Management and also featured venture capital firms Atlas Venture and Arix Bioscience. The company was incubated and seeded by Atlas Venture in 2018.
Quench is developing treatments for serious inflammatory diseases that will work by inhibiting gasdermin D, a protein that creates…
